OakChart

Neuphoria Therapeutics Inc

NEUPHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:20 PM ET

2.72+0.03 (1.12%)
2026-11-11 21:27 CET
Market cap
14.56 USD m
Revenue, TTM
1.17 USD m
Net income, TTM
-13.45 USD m
Free cash flow, TTM
-12.93 USD m
EPS diluted, TTM
-6.19
P/E
-
Compare

Price

NEUP against its 20, 50 and 200-day averages
2050200earnings
3.004.005.006.003.8M7.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NEUPclose 2.7220-day 3.1350-day 3.42200-day 4.112.7252w high

50.8% under the 52-week high of 5.53 on 22 May 2026. 52-week low 2.62 on 10 Nov 2026. Last 15 sessions, 37.0% high to low

Volume 1.15× normal · the line is the 50-bar volume average

Profile

NEUP
52-week range, 3% of the way up
2.625.53

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded in 1996 and is headquartered in Millis, MA.

Employees1
IPODec 16, 2021
Beta0.78
ATR, 14d0.13
Rel volume1.15
Short float0.24%
Insider own5.02%
Inst own41.32%

Snapshot

6 groups

Valuation

Index-
Market Cap14.72M
Enterprise Value-5.12M
Income-13.45M
Sales1.17M
Book/sh4.55
Cash/sh3.67
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1
IPODec 16, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S12.58
P/B0.60
P/C0.74
P/FCF-
EV/EBITDA-
EV/Sales-4.38
Quick Ratio27.85
Current Ratio27.85
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-6.19
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-196.42% -98.30%
Sales past 3/5Y- -
EPS Y/Y TTM79.08%
Sales Y/Y TTM-
EPS Q/Q-113.83%
Sales Q/Q-92.17%
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own5.02%
Insider Trans0.00%
Inst Own41.32%
Inst Trans5.33%
ROA-
ROE-
ROIC-54.68%
Gross Margin43.54%
Oper. Margin-835.53%
Profit Margin-1145.66%
SMA20-13.21%
SMA50-20.38%
SMA200-33.86%
Trades-

Technical

Shs Outstand5.41M
Shs Float5.14M
Short Float0.24%
Short Ratio0.38
Short Interest0.01M
52W High5.53 -50.81%
52W Low2.62 3.82%
Volatility5.61% 4.50%
ATR (14)0.13
RSI (14)19.65
Beta0.78
Rel Volume1.15
Avg Volume32.25K
Volume33,888

Performance

Perf Week-8.72%
Perf Month-19.76%
Perf Quarter-28.98%
Perf Half Y-45.38%
Perf YTD-29.90%
Perf Year-44.38%
Perf 3Y-86.97%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price7.00
Prev Close2.69
Price2.72
Change %1.12%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Sep 28, 2023UpgradeHH.C. WainwrightNeutral → Buy$8+194.1%
Sep 28, 2023ReiteratedMMaxim GroupBuy$7 → $10+267.6%
Jan 10, 2022InitiatedHH.C. WainwrightBuy$54+1,885.3%
Jan 10, 2022InitiatedEEvercore ISIOutperform$17+525.0%
Jan 10, 2022InitiatedCCantor FitzgeraldOverweight$52+1,811.8%
Jan 10, 2022InitiatedBBerenbergBuy$21+672.1%

Peers

Mkt cap
TickerCompanyMkt cap
VTGNVistagen Therapeutics Inc8.26M
TNXPTonix Pharmaceuticals Holding Corp75.63M
NMRANeumora Therapeutics Inc86.58M
SILOSILO Pharma Inc2.90M
RLMDRelmada Therapeutics Inc475.21M
ANROAlto Neuroscience Inc1.20B
MNOVMedicinova Inc69.16M
ENVBEnveric Biosciences Inc6.54M
CINGCingulate Inc67.33M
ADXNAddex Therapeutics Ltd ADR3.02M

Held by

AUM
TickerCompanyAUM
PSILAdvisorShares Psychedelics ETFAUM: 43.26M
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q42026-09-02-0.560-0.560-0.9060.000.001
2026Q32026-06-03-0.560-0.560-0.0930.000.001
2026Q22026-02-26-0.560-0.560-0.7750.000.001
2026Q12025-12-03-4.410-1.327-4.4110.000.003
2025Q42025-09-29-3.285-2.077-3.940-0.010.003
2025Q32025-05-28-1.260-1.2606.5510.000.001
2025Q22025-02-20-1.230-0.470-1.2340.660.001
2025Q12024-11-27-2.010--0.0040.00--
2024S22024-08-21-11.380-11.380-11.8801.771.771
2024S12024-02-22-11.880--11.880-0.08--
2023S12023-02-23-17.645-15.304-0.242.903
2023Q12022-11-30-8.390-8.207-0.280.271
2022S22022-10-28-14.867--0.03-1
2022S12022-02-23-20.334-8.760--0.351.721
2021S12021-02-260.0000.000-0.083.38-
2020S22020-11-280.000--4.91--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-25.519-44.132-0.1497.907.20
2020FY-13.822-26.255-0.0920.182.93
2021FY-15.691--0.100--
2022FY-30.102-31.405-0.1400.18-0.68
2023FY-29.251-25.805-0.1182.310.74
2024FY-21.622-30.993-223.380.961.62
2025FY-0.2300.377-0.23015.6510.45
2026FY-4.070-4.070-0.2300.000.00
2027FY--2.430--0.00
2028FY--2.460--0.00
2029FY--5.050---
2030FY--2.140--61.40

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q1S2025-12-031000.000.000.00
2027Q1S2025-11-071000.000.000.00
2027Q1S2025-11-061000.000.000.00
2027Q1S2025-11-051000.000.000.00
2027Q1S2025-11-041000.000.000.00
2027Q1S2025-11-031000.000.000.00
2027Q1S2025-11-021000.000.000.00
2027Q1S2025-11-011000.000.000.00
2027Q1S2025-10-311000.000.000.00
2027Q1S2025-10-301000.000.000.00
2027Q1S2025-10-291000.000.000.00
2027Q1S2025-10-281000.000.000.00
2027Q1S2025-10-271000.000.000.00
2027Q1S2025-10-261000.000.000.00

Estimate history

EPS, annual-0.405-0.149-0.092-0.1-0.14-0.118-223.384-0.228-3.06
Period201820192020202120222023202420252026
EPS, quarterly-33.982-29.208-0.004-1.2346.551-4.411-0.775-0.093-0.906
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual2.9080.5020.03100.1910015.6491.174
Period201820192020202120222023202420252026
Sales, quarterly0000.663150001.174
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual46.19452.1259.91883.966112.779122.3950.0921.9785.411
Period201820192020202120222023202420252026
Shares, quarterly0.0830.092259.8051.6291.8542.3585.3775.3775.411
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue1.171.1715.650.000.000.190.000.030.50
Cost of Goods Sold Incl. D&A0.660.660.660.660.45-1.27--
Gross Profit0.510.5114.99-0.66-0.45--1.27--
Selling, General and Administrative Excl. Other10.3210.3216.1217.2314.3419.078.446.4813.53
Research and Development-3.559.019.428.7911.604.303.918.68
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-9.81-9.81-1.13-17.89-14.79-19.68-9.71-8.09-14.25
Interest Expense----0.020.031.081.241.84
Unusual Expense4.714.71-0.24-2.210.400.68-2.52-3.44-4.21
Net Income Before Taxes-13.59-13.59-0.84-15.58-14.76-20.12-7.32-6.01-12.18
Income Taxes-0.14-0.14-0.47-0.09-0.38-4.34-0.83-2.11-4.74
Consolidated Net Income-13.45-13.45-0.37-15.49-14.38-15.78-6.49-3.90-7.44
Net Income From Continuing Operations-13.45-13.45-0.37-15.49-14.38-15.78-6.49-3.90-7.44
Net Income-13.45-13.45-0.37-15.49-14.38-15.78-6.49-4.77-7.41
EPS (Recurring)-2.87-2.31-0.33-245.66-0.12-0.14-0.13-0.14-0.21
EPS (Basic, Before Extraordinaries)-5.00-3.06-0.23-223.38-0.12-0.14-0.10-0.09-0.15
EPS (Diluted)-6.19-3.06-0.23-223.38-0.12-0.14-0.10-0.09-0.15
EBITDA-9.15-9.15-0.47-17.23-14.34-18.87-8.44-6.45-13.03
Non-Operating Income (Expense)0.930.930.050.110.430.270.95-0.13-0.31
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.320.160.630.631.440.680.030.02
Price To Sales Ratio20.1416.360.74-217,867.4649,473.99---
Gross Margin43.5443.5495.76------
Operating Margin-835.53-835.53-7.21---10,292.00--25,864.16-2,839.32
Net Margin-1,145.66-1,145.66-2.36---8,253.62--15,254.97-1,477.09
Shares Outstanding5.415.411.980.09122.39112.7883.9759.9252.12
Market Capitalization14.5614.5613.350.763,231.229,459.929,232.37--

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q32025Q22025Q12024Q4
Total Revenue1.170.000.000.0015.000.660.000.00
Cost of Goods Sold Incl. D&A0.170.170.170.170.17-0.170.17
Gross Profit1.01-0.17-0.17-0.1714.83--0.17-0.17
Selling, General and Administrative Excl. Other1.171.002.665.492.864.373.405.31
Research and Development--0.520.703.791.621.741.903.10
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.16-1.17-2.82-5.6511.98-3.70-3.57-5.48
Interest Expense-----0.00--
Unusual Expense4.88-0.39-4.144.370.98-0.81-2.87-2.79
Net Income Before Taxes-4.94-0.541.83-9.9411.18-1.93-0.94-2.72
Income Taxes-0.03-0.03-0.03-0.03-0.080.01-0.13-0.03
Consolidated Net Income-4.90-0.511.86-9.9111.26-1.94-0.80-2.69
Net Income From Continuing Operations-4.90-0.511.86-9.9111.26-1.94-0.80-2.69
Net Income-4.90-0.511.86-9.9111.26-1.94-0.80-2.69
EPS (Recurring)-0.28-0.14-1.41-3.056.95-1.59-0.01-50.45
EPS (Basic, Before Extraordinaries)-0.91-0.090.41-4.416.55-1.23-0.00-29.21
EPS (Diluted)-0.91-0.09-0.77-4.416.55-1.23-0.00-29.21
EBITDA0.00-1.00-2.66-5.4912.14-3.54-3.40-5.31
Non-Operating Income (Expense)0.100.240.510.080.180.97-0.24-0.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.160.080.090.080.100.02-
Price To Sales Ratio20.14---0.638.15--
Gross Margin85.89---98.90---
Operating Margin-13.96---79.85-558.84--
Net Margin-417.70---75.08-293.24--
Shares Outstanding5.415.385.382.361.851.63259.810.09
Market Capitalization14.567.657.2922.1610.1210,693.571,369.590.76

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments19.8714.2912.618.0623.0821.723.1510.2018.83
Short Term Receivables0.810.010.130.284.670.852.056.126.65
Inventories0.000.000.000.000.000.000.000.470.36
Other Current Assets0.390.740.460.531.000.650.530.850.70
Total Current Assets21.0715.0413.198.8728.7523.225.7417.6426.54
Net Property, Plant & Equipment0.000.110.220.220.460.650.731.762.03
Total Investments and Advances0.000.000.080.050.080.090.300.270.28
Intangible Assets7.6413.4414.169.8715.6116.7816.9617.9919.22
Deferred Tax Assets---0.38-----
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets28.7128.5927.6519.3944.9140.7423.7337.6648.07
Short Term Debt Incl. Current Port. of LT Debt0.030.150.160.100.110.134.105.934.21
Accounts Payable0.391.152.240.961.070.770.870.842.67
Other Current Liabilities0.342.921.430.771.130.870.732.912.94
Total Current Liabilities0.764.223.831.822.311.775.709.699.82
Long Term Debt0.000.000.120.160.370.524.336.9111.63
Provision for Risks Charges0.000.000.000.000.010.010.030.020.03
Deferred Tax Liabilities0.360.500.961.111.241.381.522.062.22
Other Liabilities3.004.875.251.641.861.323.437.4011.86
Total Liabilities4.119.5910.164.745.775.0015.0026.0835.54
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity24.6019.0017.4914.6539.1435.738.7311.5812.53
Total Shareholders Equity24.6019.0017.4914.6539.1435.738.7311.5812.53
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity24.6019.0017.4914.6539.1435.738.7311.5812.53
Total Liabilities & Stockholders Equity28.7128.5927.6519.3944.9140.7423.7337.6648.07
Book Value Per Share4.559.60190.120.120.350.430.150.220.27
Tangible Book Value Per Share3.132.8136.230.040.210.23-0.14-0.12-0.14
Full-Time Employees18-257----
Price to Book Ratio0.590.5174.52146.44241.72210.65---
Return on Assets-46.95-1.31-55.06-44.74-36.85-20.12-12.71-17.36-34.53
Return on Equity-61.70-2.03-78.33-53.48-42.16-29.17-36.89-61.73-89.24
Return on Invested Capital-54.68-1.95-87.98-97.11-39.95-17.89-36.54-40.09-80.46
Quick Ratio27.853.563.454.8712.4613.101.011.772.67
Current Ratio27.853.563.454.8712.4613.101.011.822.70

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-14.08-13.45-0.37-15.49-14.38-15.78-6.49-4.77-7.41
Depreciation0.690.660.660.660.450.801.271.641.22
Other Funds (Non Cash)4.704.490.28-1.311.013.27-1.62-2.15-3.23
Funds from Operations-8.69-8.300.57-16.14-12.93-11.85-6.98-5.45-9.59
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4.24-4.05-0.501.453.08-3.921.362.87-1.36
Income Taxes Payable--0.14-0.47-0.14-----
Cash from Operating Activities-12.93-12.350.08-14.68-9.85-15.77-5.62-2.58-10.94
Capital Expenditures0.000.000.000.000.00-0.00-0.00-0.01-0.07
Net Assets From Acquisitions0.000.000.000.000.000.000.00-0.680.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.130.030.180.01
Purchase or Sale of Investments0.000.000.000.000.000.32-0.090.330.00
Purchase of Investments0.000.000.000.000.000.00-0.09-0.030.00
Sale Or Maturity of Investments0.000.000.000.000.000.320.000.370.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.44-0.06-0.17-0.06
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock18.7617.921.5315.112.6019.7132.381.966.92
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock18.7617.921.5315.112.6019.7132.381.966.92
Proceedsfrom Stock Options18.7617.921.5315.112.6019.7132.381.966.92
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-8.27-5.00-3.81
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities18.7617.921.5315.112.6019.5823.53-3.593.11
Exchange Rate Effect0.010.01-0.000.08-0.16-0.58-0.010.030.06
Net Change in Cash5.845.581.600.50-7.423.6717.84-6.31-7.83
Free Cash Flow-12.93-12.350.08-14.68-9.85-15.77-5.62-2.58-11.01
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--149.26------
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-0.14-0.14-0.17-0.17

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q32025Q2
Cash & Short Term Investments19.8719.4422.2513.7317.044.34
Short Term Receivables0.811.611.110.000.020.04
Inventories0.000.000.000.000.000.00
Other Current Assets0.390.610.030.220.020.02
Total Current Assets21.0721.6623.3913.9517.094.40
Net Property, Plant & Equipment0.000.000.000.080.130.15
Total Investments and Advances0.000.000.000.000.070.07
Intangible Assets7.6413.1513.2113.3113.4213.54
Other Assets0.000.000.000.000.000.00
Total Assets28.7134.8136.6027.3430.7118.17
Short Term Debt Incl. Current Port. of LT Debt0.030.030.030.120.150.12
Accounts Payable0.390.630.521.370.751.53
Other Current Liabilities0.340.852.033.640.650.48
Total Current Liabilities0.761.512.595.121.552.13
Long Term Debt0.000.000.000.000.020.05
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.360.390.430.460.760.84
Other Liabilities3.003.483.899.252.381.39
Total Liabilities4.115.396.9014.834.724.42
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity24.6029.4229.7012.5126.0013.75
Total Shareholders Equity24.6029.4229.7012.5126.0013.75
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity24.6029.4229.7012.5126.0013.75
Total Liabilities & Stockholders Equity28.7134.8136.6027.3430.7118.17
Book Value Per Share4.555.475.525.3114.028.44
Tangible Book Value Per Share3.133.033.07-0.346.780.13
Full-Time Employees1-----
Price to Book Ratio0.590.740.730.840.68625.91
Return on Invested Capital-19.94-1.726.28-79.1943.29-14.08
Quick Ratio27.8514.319.042.7211.012.06
Current Ratio27.8514.319.042.7211.012.06

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q32025Q2
Net Income-5.19-0.841.85-9.9110.94-1.91
Depreciation0.180.190.170.170.150.16
Other Funds (Non Cash)5.99-0.86-4.984.550.73-1.20
Funds from Operations1.09-1.55-3.03-5.1911.81-2.95
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.10-2.32-3.421.40-0.59-0.31
Income Taxes Payable----0.03-0.08-
Cash from Operating Activities1.19-3.87-6.45-3.7911.23-3.26
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.110.7014.693.250.800.23
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.110.7014.693.250.800.23
Proceedsfrom Stock Options0.110.7014.693.250.800.23
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.33-0.33
Other Financing Activities Uses0.000.000.000.000.33-0.33
Cash from Financing Activities0.110.7014.693.251.13-0.11
Exchange Rate Effect-0.820.560.30-0.020.08-0.27
Net Change in Cash0.48-2.618.54-0.5612.44-3.64
Free Cash Flow1.19-3.87-6.45-3.7911.23-3.26
Price to Free Cash Flow----19.55-

Revenue breakdown

Pharmaceutical Preparations2025: 15.65M 2026: 1.17M
United States2025: 15.65M 2026: 1.17M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.24%0.0M5.1M31.98K
2026-10-150.13%0.0M5.1M159.17K
2026-09-300.39%0.0M5.1M176.28K
2026-09-150.50%0.0M5.0M189.68K
2026-08-311.30%0.1M5.0M196.76K
2026-08-140.85%0.0M4.9M197.82K
2026-07-311.33%0.1M4.9M196.86K
2026-07-150.31%0.0M4.9M64.80K
2026-06-300.32%0.0M4.9M55.79K
2026-06-150.47%0.0M4.9M51.55K
2026-05-292.15%0.0M1.7M52.89K
2026-05-151.15%0.0M1.7M48.35K
2026-04-302.69%0.0M1.7M47.45K
2026-04-151.36%0.0M1.7M49.29K
2026-03-311.57%0.0M1.7M48.61K
2026-03-130.72%0.0M1.7M50.05K
2026-02-270.84%0.0M1.7M52.26K
2026-02-131.94%0.0M1.7M63.78K
2026-01-302.16%0.0M1.7M111.62K
2026-01-152.38%0.0M1.7M1.57M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-238-KCurrent report2026-10-23SEC
2026-10-05SCHEDULE 13GSEC
2026-09-1810-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-18DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-18DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-18DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-02SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-24DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-248-KCurrent report2026-07-20SEC
2026-05-268-KCurrent report2026-05-21SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-02-1710-QQuarterly report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-06SCHEDULE 13G/ASEC
2026-01-214Statement of changes in beneficial ownership of securities2026-01-20SEC
2026-01-214Statement of changes in beneficial ownership of securities2026-01-20SEC
2026-01-214Statement of changes in beneficial ownership of securities2026-01-20SEC
2026-01-088-KCurrent report2025-12-31SEC
2025-12-29SCHEDULE 13D/ASEC
2025-12-188-KCurrent report2025-12-18SEC
2025-12-178-KCurrent report2025-12-12SEC
2025-12-08DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2025-12-08DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2025-12-08DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2025-12-04DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2025-12-03DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2025-12-02DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC
2025-12-02SCHEDULE 13D/ASEC
2025-12-01DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2025-11-28SCHEDULE 13D/ASEC
2025-11-26DFAN14ADefinitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Lynx1 Capital Management LP16.20%
AdvisorShares Investments LLC5.78%
VANGUARD CAPITAL MANAGEMENT LLC3.21%
Shay Capital LLC2.88%
BALYASNY ASSET MANAGEMENT L.P.2.63%
CITADEL ADVISORS LLC1.34%
GEODE CAPITAL MANAGEMENT, LLC0.94%
Ikarian Capital, LLC0.88%
VANGUARD FIDUCIARY TRUST CO0.63%
ADAR1 Capital Management, LLC0.56%

Funds

Fund% owned
AdvisorShares Psychedelics ETF4.68%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.04%
VANGUARD EXTENDED MARKET INDEX FUND1.17%
Fidelity Extended Market Index Fund0.70%
Fidelity Series Total Market Index Fund0.15%
Fidelity Total Market Index Fund0.10%
Fidelity Nasdaq Composite Index Fund0.04%

OakChart. NEUP. Cached 15 minutes.

Some panels did not load: insider.